Who is sponsoring NCT01829477?

NCT01829477 is sponsored by Takeda.

What condition does NCT01829477 study?

NCT01829477 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01829477?

Interventions: TAK-875, TAK-875 Placebo, Glimepiride.

What is the status of NCT01829477?

NCT01829477 is currently TERMINATED.

Last reviewed 2016-04-24 · How we verify

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes

NCT01829477 Phase 3 TERMINATED Results posted

The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	TERMINATED
Enrolment	33
Start date	2013-04
Completion	2014-02

Conditions

Diabetes Mellitus, Type 2

Interventions

TAK-875
TAK-875 Placebo
Glimepiride

Primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — Baseline and Week 24
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.

Countries

United States, Bulgaria, Canada, Hungary, Poland, Romania, Slovakia